Literature DB >> 22927007

ERα signaling regulates MMP3 expression to induce FasL cleavage and osteoclast apoptosis.

Alejandro J Garcia1, Colton Tom, Miriam Guemes, Gloria Polanco, Maria E Mayorga, Korinna Wend, Gustavo A Miranda-Carboni, Susan A Krum.   

Abstract

The benefits of estrogens on bone health are well established; how estrogens signal to regulate bone formation and resorption is less well understood. We show here that 17β-estradiol (E2)-induced apoptosis of bone-resorbing osteoclasts is mediated by cleavage and solubilization of osteoblast-expressed Fas ligand (FasL). U2OS-ERα osteoblast-like cells expressing an EGFP-tagged FasL at the C-terminus showed decreased fluorescence after E2 treatment, indicative of a cleavage event. Treatment of U2OS-ERα cultures with a specific MMP3 inhibitor in the presence of E2 blocked FasL cleavage and showed an increase in the number of EGFP-FasL+ cells. siRNA experiments successfully knocked down MMP3 expression and restored full-length FasL to basal levels. E2 treatment of both human and murine primary osteoblasts showed upregulation of MMP3 mRNA expression, and calvarial organ cultures showed increased expression of MMP3 protein and colocalization with the osteoblast-specific RUNX2 after E2 treatment. In addition, osteoblast cell cultures derived from ERαKO mice showed decreased expression of MMP3 but not MMP7 and ADAM10, two known FasL proteases, demonstrating that ERα signaling regulates MMP3. Also, conditioned media of E2-treated calvarial osteoblasts showed an approximate sixfold increase in the concentration of soluble FasL, indicating extensive cleavage, and soluble FasL concentrations were reduced in the presence of a specific MMP3 inhibitor. Finally, to show the role of soluble FasL in osteoclast apoptosis, human osteoclasts were cocultured with MC3T3 osteoblasts. Both a specific MMP3 inhibitor and an MMP inhibitor cocktail preserved osteoclast differentiation and survival in the presence of E2 and demonstrate the necessity of MMP3 for E2-induced osteoclast apoptosis. These experiments further define the molecular mechanism of estrogen's bone-protective effects by inducing osteoclast apoptosis through upregulation of MMP3 and FasL cleavage.
Copyright © 2013 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22927007      PMCID: PMC3524410          DOI: 10.1002/jbmr.1747

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  26 in total

1.  Unique ERalpha cistromes control cell type-specific gene regulation.

Authors:  Susan A Krum; Gustavo A Miranda-Carboni; Mathieu Lupien; Jerome Eeckhoute; Jason S Carroll; Myles Brown
Journal:  Mol Endocrinol       Date:  2008-09-25

2.  Assessing new bone formation in neonatal calvarial organ cultures.

Authors:  Khalid S Mohammad; John M Chirgwin; Theresa A Guise
Journal:  Methods Mol Biol       Date:  2008

3.  Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption.

Authors:  K Kusano; C Miyaura; M Inada; T Tamura; A Ito; H Nagase; K Kamoi; T Suda
Journal:  Endocrinology       Date:  1998-03       Impact factor: 4.736

4.  Inhibition of osteoblastic metalloproteinases in mice prevents bone loss induced by oestrogen deficiency.

Authors:  Corinne Schiltz; Caroline Marty; Marie-Christine de Vernejoul; Valerie Geoffroy
Journal:  J Cell Biochem       Date:  2008-08-01       Impact factor: 4.429

5.  The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone.

Authors:  Marta Martin-Millan; Maria Almeida; Elena Ambrogini; Li Han; Haibo Zhao; Robert S Weinstein; Robert L Jilka; Charles A O'Brien; Stavros C Manolagas
Journal:  Mol Endocrinol       Date:  2010-01-06

6.  Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts.

Authors:  Takashi Nakamura; Yuuki Imai; Takahiro Matsumoto; Shingo Sato; Kazusane Takeuchi; Katsuhide Igarashi; Yoshifumi Harada; Yoshiaki Azuma; Andree Krust; Yoko Yamamoto; Hiroshi Nishina; Shu Takeda; Hiroshi Takayanagi; Daniel Metzger; Jun Kanno; Kunio Takaoka; T John Martin; Pierre Chambon; Shigeaki Kato
Journal:  Cell       Date:  2007-09-07       Impact factor: 41.582

7.  Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival.

Authors:  Susan A Krum; Gustavo A Miranda-Carboni; Peter V Hauschka; Jason S Carroll; Timothy F Lane; Leonard P Freedman; Myles Brown
Journal:  EMBO J       Date:  2008-01-24       Impact factor: 11.598

8.  Differential regulation of MMP-13 (collagenase-3) and MMP-3 (stromelysin-1) in mouse calvariae.

Authors:  C Peeters-Joris; K Hammani; C F Singer
Journal:  Biochim Biophys Acta       Date:  1998-10-21

9.  Unraveling estrogen action in osteoporosis.

Authors:  Susan A Krum; Myles Brown
Journal:  Cell Cycle       Date:  2008-02-29       Impact factor: 4.534

10.  The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells.

Authors:  V Kirkin; N Cahuzac; F Guardiola-Serrano; S Huault; K Lückerath; E Friedmann; N Novac; W S Wels; B Martoglio; A-O Hueber; M Zörnig
Journal:  Cell Death Differ       Date:  2007-06-08       Impact factor: 15.828

View more
  28 in total

1.  A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling.

Authors:  Daniel R Jones
Journal:  Ann Transl Med       Date:  2015-08

Review 2.  Minireview: nuclear receptor regulation of osteoclast and bone remodeling.

Authors:  Zixue Jin; Xiaoxiao Li; Yihong Wan
Journal:  Mol Endocrinol       Date:  2014-12-30

3.  Effect of a single injection of testosterone enanthate on 17β estradiol and bone turnover markers in hypogonadal male patients.

Authors:  V Camozzi; G Bonanni; A Frigo; M Piccolo; S Ferasin; M Zaninotto; M Boscaro; G Luisetto
Journal:  J Endocrinol Invest       Date:  2014-10-16       Impact factor: 4.256

4.  Estrogens and androgens inhibit association of RANKL with the pre-osteoblast membrane through post-translational mechanisms.

Authors:  Anthony Martin; Jiali Yu; Jian Xiong; Aysha B Khalid; Benita Katzenellenbogen; Sung Hoon Kim; John A Katzenellenbogen; Suchinda Malaivijitnond; Yankel Gabet; Susan A Krum; Baruch Frenkel
Journal:  J Cell Physiol       Date:  2017-05-11       Impact factor: 6.384

5.  Osteoblast-induced osteoclast apoptosis by fas ligand/FAS pathway is required for maintenance of bone mass.

Authors:  L Wang; S Liu; Y Zhao; D Liu; Y Liu; C Chen; S Karray; S Shi; Y Jin
Journal:  Cell Death Differ       Date:  2015-03-06       Impact factor: 15.828

6.  Mature osteoclast-derived apoptotic bodies promote osteogenic differentiation via RANKL-mediated reverse signaling.

Authors:  Qinyu Ma; Mengmeng Liang; Yutong Wu; Ning Ding; Lianli Duan; Tao Yu; Yun Bai; Fei Kang; Shiwu Dong; Jianzhong Xu; Ce Dou
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

Review 7.  Osteoblast-osteoclast interactions.

Authors:  Xiao Chen; Zhongqiu Wang; Na Duan; Guoying Zhu; Edward M Schwarz; Chao Xie
Journal:  Connect Tissue Res       Date:  2017-03-21       Impact factor: 3.417

Review 8.  Estrogens and Androgens in Skeletal Physiology and Pathophysiology.

Authors:  Maria Almeida; Michaël R Laurent; Vanessa Dubois; Frank Claessens; Charles A O'Brien; Roger Bouillon; Dirk Vanderschueren; Stavros C Manolagas
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

Review 9.  Sex steroid actions in male bone.

Authors:  Dirk Vanderschueren; Michaël R Laurent; Frank Claessens; Evelien Gielen; Marie K Lagerquist; Liesbeth Vandenput; Anna E Börjesson; Claes Ohlsson
Journal:  Endocr Rev       Date:  2014-09-09       Impact factor: 19.871

10.  Estrogen receptor α in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3.

Authors:  Spencer Slavin; Chiuan-Ren Yeh; Jun Da; Shengqiang Yu; Hiroshi Miyamoto; Edward M Messing; Elizabeth Guancial; Shuyuan Yeh
Journal:  Carcinogenesis       Date:  2013-12-28       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.